mizoribine has been researched along with dipyridamole in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Hosono, S; Kato, K; Murakami, R; Muramatsu, M; Omote, A; Sano, H; Sugimoto, Y; Tanaka, H; Watanabe, Y | 1 |
| Ikeda, M; Kuwajima, H; Okada, M; Sugimoto, K; Takemura, T; Yagi, K; Yanagida, H | 1 |
| Hataya, H; Honda, M; Iijima, K; Ishikura, K; Nakanishi, K; Yoshikawa, N | 1 |
| Yoshikawa, N | 1 |
| Iijima, K; Kamei, K; Nakanishi, K; Nozu, K; Sasaki, S; Shima, Y; Tanaka, R; Togawa, H; Yoshikawa, N | 1 |
| Hataya, H; Honda, M; Iijima, K; Ishikura, K; Kaku, Y; Matsuyama, T; Nakanishi, K; Nozu, K; Sako, M; Shima, Y; Tanaka, R; Yoshikawa, N | 1 |
1 review(s) available for mizoribine and dipyridamole
| Article | Year |
|---|---|
[Treatment of childhood IgA nephropathy].
Topics: Azathioprine; Child; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medicine; Glomerulonephritis, IGA; Heparin; Humans; Practice Guidelines as Topic; Prednisolone; Prognosis; Randomized Controlled Trials as Topic; Ribonucleosides; Warfarin | 2008 |
3 trial(s) available for mizoribine and dipyridamole
| Article | Year |
|---|---|
Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Topics: Adolescent; Adult; Age of Onset; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Child; Child, Preschool; Dipyridamole; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Kidney; Male; Prednisone; Proteinuria; Ribonucleosides; Treatment Outcome; Vasodilator Agents | 2003 |
Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
Topics: Biopsy; Child; Dipyridamole; Disease Progression; Female; Follow-Up Studies; Glomerulonephritis, IGA; Glucocorticoids; Humans; Immunoglobulin A; Immunosuppressive Agents; IMP Dehydrogenase; Kidney Glomerulus; Male; Pilot Projects; Platelet Aggregation Inhibitors; Prednisolone; Prospective Studies; Proteinuria; Ribonucleosides; Severity of Illness Index; Treatment Outcome | 2008 |
Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
Topics: Adolescent; Biopsy; Child; Dipyridamole; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Male; Prednisolone; Prospective Studies; Proteinuria; Ribonucleosides; Severity of Illness Index; Treatment Outcome; Warfarin | 2018 |
5 other study(ies) available for mizoribine and dipyridamole
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies -- related scleroderma renal crisis treated with double-filtration plasmapheresis.
Topics: Acute Kidney Injury; Antibodies, Antineutrophil Cytoplasmic; Anticoagulants; Autoimmune Diseases; Biopsy, Needle; Combined Modality Therapy; Dipyridamole; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Methylprednisolone; Middle Aged; Neutrophils; Peroxidase; Plasmapheresis; Prednisolone; Ribonucleosides; Scleroderma, Systemic | 1997 |
Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
Topics: Anti-Inflammatory Agents; Anticoagulants; Azathioprine; Child; Dipyridamole; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Immunosuppressive Agents; Kidney Glomerulus; Male; Prednisolone; Retrospective Studies; Ribonucleosides; Survival Rate; Treatment Outcome; Vasodilator Agents; Warfarin | 2011 |